Clinical and Virological Outcome of Monoclonal Antibody Therapies Across SARS-CoV-2 Variants in 245 Immunocompromised Patients: A Multicenter Prospective Cohort Study.

doi:10.1093/cid/ciae026

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Clinical and Virological Outcome of Monoclonal Antibody Therapies Across SARS-CoV-2 Variants in 245 Immunocompromised Patients: A Multicenter Prospective Cohort Study.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 14 Jun 2024

Huygens Sammy, GeurtsvanKessel Corine, Gharbharan Arvind, Bogers Susanne, Worp Nathalie, Boter Marjan, Bax Hannelore I, Kampschreur Linda M, Hassing Robert-Jan, Fiets Roel B, Levenga Henriette, Afonso Pedro Miranda, Koopmans Marion, Rijnders Bart J A, Oude Munnink Bas B

Abstract excerpt

BACKGROUND: Immunocompromised patients (ICPs) have an increased risk for a severe and prolonged COVID-19. SARS-CoV-2 monoclonal antibodies (mAbs) were extensively used in these patients, but data from randomized trials that focus on ICPs are lacking. We evaluated the clinical and virological outcome of COVID-19 in ICPs treated with mAbs across SARS-CoV-2 variants. METHODS: In this multicenter prospective cohort...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Monoclonal, Humanized

Share to Antiviral Agents

Share to COVID-19

Share to COVID-19 Drug Treatment

Share to Immunocompromised Host

Share to SARS-CoV-2

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 38445721
DOI: 10.1093/cid/ciae026
PMCID: PMC11175671

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical and Virological Outcome of Monoclonal Antibody Therapies Across SARS-CoV-2 Variants in 245 Immunocompromised Patients: A Multicenter Prospective Cohort Study.PMID 38445721Read ↗

Genotypic and Predicted Phenotypic Analysis of SARS-CoV-2 Omicron Subvariants in Immunocompromised Patients with COVID-19 Following Tixagevimab-Cilgavimab ProphylaxisSemantic proximity Read ↗

EFFECTIVENESS OF CASIRIVIMAB-IMDEVIMAB AND SOTROVIMAB MONOCLONAL ANTIBODY TREATMENT AMONG HIGH-RISK PATIENTS WITH SARS-CoV-2 INFECTION: A REAL-WORLD EXPERIENCESemantic proximity Read ↗

Host immunological responses facilitate development of SARS-CoV-2 mutations in patients receiving monoclonal antibody treatments.Semantic proximity Read ↗

Neutralizing anti-spike monoclonal antibodies for COVID-19 in vulnerable populations: lessons learned and future directions.Semantic proximity Read ↗

Influence of treatment with neutralizing monoclonal antibodies on the SARS-CoV-2 nasopharyngeal load and quasispecies.Semantic proximity Read ↗

Effectiveness and Tolerability of Early Treatment with Monoclonal Antibodies against SARS-Cov-2: Results from A Real-Life Study before Omicron SurgeSemantic proximity Read ↗

Longitudinal Analysis of Escape Mutations in SARS-CoV-2 Omicron Variants after Sotrovimab Use in Immunodeficient PatientsSemantic proximity Read ↗

Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4 and BA.5 in patients receiving monoclonal antibodiesSemantic proximity Read ↗

Evolution of spike mutations following antibody treatment in two immunocompromised patients with persistent COVID-19 infection.Semantic proximity Read ↗

SARS-CoV-2 evolution and evasion from multiple antibody treatments in a cancer patientSemantic proximity Read ↗

The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies.Semantic proximity Read ↗

Seroneutralization of Omicron BA.1 and BA.2 in patients receiving anti-SARS-CoV-2 monoclonal antibodiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.